Browse

11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET

DC Field Value Language
dc.contributor.authorKim, Sungeun-
dc.contributor.authorChung, June-Key-
dc.contributor.authorIm, So-Hyang-
dc.contributor.authorJeong, Jae Min-
dc.contributor.authorLee, Dong Soo-
dc.contributor.authorKim, Dong Gyu-
dc.contributor.authorJung, Hee Won-
dc.contributor.authorLee, Myung Chul-
dc.date.accessioned2010-01-08T05:22:41Z-
dc.date.available2010-01-08T05:22:41Z-
dc.date.issued2004-08-17-
dc.identifier.citationEur J Nucl Med Mol Imaging. 2005 Jan;32(1):52-9. Epub 2004 Aug 10.en
dc.identifier.issn1619-7070 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15309332-
dc.identifier.urihttp://hdl.handle.net/10371/28906-
dc.description.abstractPURPOSE: The purpose of this study was to compare the prognostic value of 11C-methionine (MET) and 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in glioma patients. METHODS: The study population comprised 47 patients with gliomas (19 glioblastoma, 28 others). Pretreatment magnetic resonance imaging, MET PET and FDG PET were performed within a time interval of 2 weeks in all patients. The uptake ratio and standard uptake values were calculated. Univariate and multivariate analyses were done to determine significant prognostic factors. Ki-67 index was measured by immunohistochemical staining, and compared with FDG and MET uptake in glioma. RESULTS: Among the several clinicopathological prognostic factors, tumour pathology (glioblastoma or not), age (> or =60 or <60 years), Karnofsky performance status (KPS) (> or =70 or <70) and MET PET (higher uptake or not compared with normal cortex) were found to be significant predictors by univariate analysis. In multivariate analysis, tumour pathology, KPS and MET PET were identified as significant independent predictors. The Ki-67 proliferation index was significantly correlated with MET uptake (r=0.64), but not with FDG uptake. CONCLUSION: Compared with FDG PET in glioma, MET PET was an independent significant prognostic factor and MET uptake was correlated with cellular proliferation. MET PET may be a useful biological prognostic marker in glioma patients.en
dc.language.isoen-
dc.publisherSpringer Verlagen
dc.subjectBrain Neoplasms/*mortality/*radionuclide imaging/therapyen
dc.subjectFemaleen
dc.subjectFluorodeoxyglucose F18/*diagnostic useen
dc.subjectGlioma/*mortality/*radionuclide imaging/therapyen
dc.subjectHumansen
dc.subjectKorea/epidemiologyen
dc.subjectMaleen
dc.subjectMethionine/*diagnostic useen
dc.subjectMiddle Ageden
dc.subjectPositron-Emission Tomography/methods/statistics & numerical dataen
dc.subjectPrevalenceen
dc.subjectPrognosisen
dc.subjectRadiopharmaceuticals/diagnostic useen
dc.subjectReproducibility of Resultsen
dc.subjectRetrospective Studiesen
dc.subjectRisk Assessment/*methodsen
dc.subjectRisk Factorsen
dc.subjectSensitivity and Specificityen
dc.subjectSurvival Analysisen
dc.title11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PETen
dc.typeArticleen
dc.contributor.AlternativeAuthor김성은-
dc.contributor.AlternativeAuthor정준기-
dc.contributor.AlternativeAuthor임소향-
dc.contributor.AlternativeAuthor정재민-
dc.contributor.AlternativeAuthor이동수-
dc.contributor.AlternativeAuthor김동규-
dc.contributor.AlternativeAuthor정희원-
dc.contributor.AlternativeAuthor이명철-
dc.identifier.doi10.1007/s00259-004-1598-6-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Nuclear Medicine (핵의학전공)Journal Papers (저널논문_핵의학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse